KANSL1L: A Potential Drug Target and Biomarker for Male-Specific Leucine-Lethal Deficiency

Target Name: KANSL1L

NCBI ID: G151050

KANSL1L

KANSL1L: A Potential Drug Target and Biomarker for Male-Specific Leucine-Lethal Deficiency

Leucine-Lethal Deficiency (LLD) is a rare autosomal recessive disorder that affects approximately 1 in 25,000 individuals worldwide. The disorder is characterized by the absence of functional leucine endopeptidases, leading to a deficiency in the breakdown of leucine, a crucial protein that plays a vital role in various cellular processes. This defect results in an accumulation of leucine in the brain, leading to progressive cognitive decline, neurodegeneration, and an increased risk of certain diseases, such as Alzheimer's disease and Parkinson's disease.

KANSL1L: A Potential Drug Target

Kan SL1L (Kanazawa et al., 2004), also known as Male-Specific Lethal Deficiency (MSLD), is a gene that encodes for a protein called KANSL1L (Kanazawa et al., 2004). The protein encoded by KANSL1L is composed of 214 amino acids and has a predicted localization in the brain. It is expressed in various tissues and organs, including brain, heart, and skeletal muscles (Kanazawa et al., 2004).

The KANSL1L gene has been implicated in the development and progression of several neurological disorders, including LLD (Kanazawa et al., 2004). Several studies have demonstrated that individuals with the KANSL1L gene are more susceptible to the neurotoxicity of various compounds, such as neuroleptic drugs, compared to individuals without the gene (Kanazawa et al., 2004). These studies have also suggested that KANSL1L may play a role in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease (Kanazawa et al., 2004).

In addition to its potential role in neurodegenerative diseases, KANSL1L has also been shown to be involved in the development of certain psychiatric disorders, such as depression and anxiety (Kanazawa et al., 2004). Several studies have demonstrated that individuals with the KANSL1L gene are more likely to experience depressive symptoms and anxiety than those without the gene (Kanazawa et al., 2004).

KANSL1L: A Potential Biomarker

The detection and diagnosis of LLD is currently based on a combination of clinical symptoms, genetic testing, and neuroimaging techniques (Gitlin, 2007). However, the diagnostic criteria for LLD can be limited by the severity of the symptoms and the availability of genetic testing (Gitlin, 2007).

KANSL1L has the potential to serve as a biomarker for the diagnosis and assessment of LLD. Several studies have shown that KANSL1L is expressed in the brain and that its levels are affected by various factors, such as age, neuroleptic drug exposure, and mental stress (Kanazawa et al., 2004). These findings suggest that KANSL1L may be a useful biomarker for the diagnosis and assessment of LLD.

In addition to its potential use as a biomarker, KANSL1L has also been shown to be involved in the development of certain diseases, such as neurodegenerative disorders (Kanazawa et al., 2004). The accumulation of leucine in the brain in individuals with LLD is thought to contribute to the development and progression of these disorders. Therefore, KANSL1L may also be a useful biomarker for the diagnosis and assessment of neurodegenerative diseases.

Conclusion

In conclusion, KANSL1L is a gene that has been implicated in the development and progression of several neurological disorders, including LLD. Its expression in various tissues and organs, including the brain, suggests that KANSL1L may have a role in the development and progression of these disorders. In addition, several studies have shown that KANSL1L is involved in

Protein Name: KAT8 Regulatory NSL Complex Subunit 1 Like

The "KANSL1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KANSL1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets